Dynamics of antibody titers to SARS-CoV-2 and clinical outcomes after sotrovimab pre-exposure prophylaxis early after allogeneic hematopoietic stem cell transplantation

1

Allogeneic hematopoietic cell transplantation recipients are at increased risk for severe COVID-19 and mortality compared to the general population.
2

Sotrovimab was used as pre-exposure prophylaxis for COVID-19 in newly transplanted alloHCT recipients due to the unavailability of tixagevimab/cilgavimab.
3

After sotrovimab administration, anti-S/RBD total Ig levels increased significantly, with 86.1% of patients showing levels above the upper limit of detection by day 60.
4

Neutralizing antibody titers peaked on day 7 post-sotrovimab, with 100% of patients maintaining detectable antibodies against BA.1 at day 30.
5

Breakthrough SARS-CoV-2 infections occurred in 19.4% of patients, with most cases being asymptomatic and all patients surviving at day 90.

Bone Marrow Transplantation

by Gioele Capoferri, Carla Simone Walti, Pascal Urwyler, Silvio Ragozzino, Jakob R. Passweg, Jörg Halter, Manuel Battegay, Veronika Baettig, Maja Weisser, Brice Arnold, Benedict Morin, Yukino Guetlin, Diana Albertos Torres, Güliz Tuba Barut, Volker Thiel, Adrian Egli, Beatrice Drexler, Nina Khanna
February 16, 2023

1